Legal & General Group
TCRR

Legal & General Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Legal & General Group’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,381
Closed -$7K – 3730
2022
Q1 		$7K Hold
2,381
– – ﹤0.01% 3477
2021
Q4 		$11K Sell
2,381
-6,054
-72% -$37.8K ﹤0.01% 3450
2021
Q3 		$72K Buy
8,435
+4,883
+137% +$69K ﹤0.01% 2904
2021
Q2 		$58K Sell
3,552
-42
-1% -$848 ﹤0.01% 2909
2021
Q1 		$80K Buy
3,594
+209
+6% +$5.7K ﹤0.01% 2679
2020
Q4 		$104K Buy
3,385
+1,171
+53% +$29.6K ﹤0.01% 2582
2020
Q3 		$45K Buy
2,214
+104
+5% +$1.83K ﹤0.01% 2736
2020
Q2 		$32K Buy
2,110
+538
+34% +$6.21K ﹤0.01% 2870
2020
Q1 		$10K Sell
1,572
-426
-21% -$5.21K ﹤0.01% 3168
2019
Q4 		$29K Buy
1,998
+42
+2% +$649 ﹤0.01% 3067
2019
Q3 		$29K Buy
1,956
+1,411
+259% +$22K ﹤0.01% 2987
2019
Q2 		$8K Buy
+545
New +$8.7K ﹤0.01% 3404

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Legal & General Group's TCRR Position: Q2 2022 in Review

Legal & General Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2022, closing a stake of 2,381 shares — an estimated $7K sold.

Legal & General Group first reported a position in TCRR in Q2 2019 and held it in 12 quarters. The position peaked at $104K in Q4 2020. 83 funds tracked by Wall St. Rank hold TCRR as of Q2 2022.

  • Legal & General Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 2,381 TCR2 Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $7K.
  • Legal & General Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • Legal & General Group's TCR2 Therapeutics Inc. Common Stock position peaked at $104K in Q4 2020.
  • 83 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.